13F-HR filed by Patient Square Capital LP
Patient Square Capital LP filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-10, with 24 holding rows worth $373,857,431.
- Accession
- 0001819257-25-000002
- Filer
- CIK 1819257
- Filed
- 2025-11-10
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 24 entries on the cover page, a total value of $373,857,431 stated on the cover page (in dollars after the unit check, H1), rows summing to $373,857,431 with VALUE read as dollars as filed, 13F file number 028-22927. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | G76279101 | SHS | 12,480,000 | $188,822,400 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 326,400 | $47,004,864 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 1,011,839 | $14,408,587 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 151,833 | $12,890,622 | dollars as filed | |
| CIDARA THERAPEUTICS INC | 171757206 | COM NEW | 121,000 | $11,586,960 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 15,500 | $11,432,180 | dollars as filed | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 400,000 | $9,096,000 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 345,381 | $8,617,256 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 715,000 | $8,358,350 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 104,262 | $7,643,447 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 133,827 | $5,371,816 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 92,592 | $5,240,707 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 250,838 | $5,134,654 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 100,000 | $4,940,000 | dollars as filed | |
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 125,000 | $4,918,750 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 74,000 | $4,889,920 | dollars as filed | |
| UNIQURE NV | N90064101 | SHS | 75,000 | $4,377,750 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 316,312 | $4,298,680 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 437,237 | $4,040,070 | dollars as filed | |
| ALLOGENE THERAPEUTICS INC | 019770106 | COM | 2,981,396 | $3,696,931 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 135,182 | $3,460,659 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 100,000 | $1,271,000 | dollars as filed | |
| PERSPECTIVE THERAPEUTICS INC | 46489V302 | COMMON STOCK | 349,323 | $1,198,178 | dollars as filed | |
| GERON CORP | 374163103 | COM | 845,000 | $1,157,650 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001819257-25-000002 | this filing | 2025-11-10 | acceptance time not in the bulk data set |